"Bioactive Compounds in Diabetes Management: Antidiabetic Properties and Therapeutic Potential."

Diabetes mellitus (DM) is a global health emergency that is characterised by persistently elevated blood sugar levels and is associated with dire consequences. The potential of bioactive substances as preventative and supplemental medicines in the management of diabetes is being highlighted by emerging research. This review examines various classes of bioactive compounds that exhibit antidiabetic properties, encompassing phytochemicals (polyphenols, flavonoids, alkaloids, terpenoids), nutraceuticals (vitamins, minerals, omega-3 fatty acids, probiotics), and synthetic compounds (oral hypoglycemic agents, insulin sensitizers, DPP-4 inhibitors). This analysis analytically evaluates the mechanisms by which these compounds exert antidiabetic effects, such as insulin sensitisation, antioxidant activity, anti-inflammatory effects, inhibition of carbohydrate hydrolysing enzymes, regulation of glucose uptake, and modulation of gastrointestinal microbiota. Clinical trials in humans and studies in animals provide evidence for the effectiveness of these compounds in enhancing glycemic control and mitigating complications associated with diabetes. Future research directions emphasize the need for novel compound discovery, personalized medicine approaches, and robust safety assessments. The review also addresses challenges related to bioavailability, stability, standardization, and quality control of bioactive compounds. Integrating bioactive compounds into diabetes management strategies offers promising avenues for enhancing therapeutic outcomes and overall patient health. This comprehensive overview underscores the potential of bioactive compounds to complement traditional therapies and improve diabetes care.